Detail akcie Abivax online

Business Summary: Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Abivax SA revenues was not reported. Net loss increased 22% to EUR52.4M. Higher net loss reflects Interest Expense on Loans increase of 90% to EUR4.5M (expense), Personnel costs - Research & Development increase of 8% to EUR29.2M (expense), Interest Income decrease of 66% to EUR859K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.68 to -EUR0.83.